CFO Alan Musso plans to retire later this year to spend more time with his family and other outside interests. Musso will remain in his role until a successor is named and has agreed to serve as a consultant thereafter to support a transition. Fulcrum will initiate a search to identify a successor.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics Highlights Q1 Results and Sickle Cell Progress
- Fulcrum Therapeutics (FULC) Q1 Earnings Cheat Sheet
- Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
- Regulatory Tailwinds and Clinical Momentum Support Buy Rating on Fulcrum Ahead of Key 2Q26 FDA Milestones
- Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study